Ozempic is giving people 'temporal hollowing.' Doctors are sounding an alarm.

Multiple outlets have amplified the story. UNILAD Tech reported that the rising “Ozempic face” side effect is fueling a cosmetic treatment boom as a quick fix. A report from dars.gov.et referenced a Swiss firm that observes heightened demand for aesthetic procedures linked to the phenomenon. Medscape framed the issue as a question of whether Ozempic face is reshaping aesthetic care.

CNBC noted a Botox boom driven by a “sagging face” trend, again citing the Swiss firm’s data. USA Today underscored doctors’ alarm over the temporal hollowing reports. Ozempic, originally approved for type‑2 diabetes and later popularized for weight‑loss therapy, belongs to the GLP‑1 class of drugs. Its metabolic benefits have been widely documented, but the emerging focus on facial aesthetics marks a shift from traditional safety discussions.

Temporal hollowing refers specifically to the temples, a region not typically associated with drug‑induced changes, making the observation notable for both clinicians and the cosmetic industry. Future coverage is expected to track the Swiss firm’s demand figures and any further statements from medical societies. Observers will watch whether the surge in Botox and related procedures translates into sustained market growth, and whether regulatory bodies issue guidance on managing the aesthetic side effect. The trajectory of Ozempic prescribing patterns may also be reassessed as the cosmetic implications become more visible.